This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Adentri (oral)

Biogen, Inc.

Drug Names(s): Tonapofylline, BG9928, CVT-124, BG9719, A1 Adenosine Receptor Antagonist

Description: BioMedTracker has separate drug profiles for the oral and intravenous formulations of Adentri. Please also see Adentri (intravenous).

ADENTRI (oral) is an A1 adenosine receptor antagonist.

Deal Structure: Biogen
In March 1997, Biogen licensed rights to develop adenosine A1 receptor inhibitors from CV Therapeutics. CV Therapeutics' original compound was known as CVT-124 (BG9719).

Astellas
In January 2009, Astellas Pharma announced that it submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash.

Gilead
In March 2009, Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. The acquisition was completed in April 2009.

Partners: Gilead Sciences, Inc.

Adentri (oral) News

Scrip Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Scrip Novo's Ozempic Soars As Focus Shifts To Oral Semaglutide

Scrip ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Scrip Biohaven's Oral Rimegepant Poised To Alter Migraine Market

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug